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this disease focused for the dermatologist, and additionally 
it emphasizes the recent consensus documents on the vari-
ous aspects of chronic GVHD of the National Institute of 
Health.  Copyright © 2008 S. Karger AG, Basel 
 Evolution of Hematopoietic Cell Transplantation 
 Hematopoietic stem cell transplantation (HSCT) in its 
current form evolved over the last 50 years from research 
initially aimed at treating the sequelae of radiation expo-
sure that were feared in the ‘Cold War’ and Nuclear Age 
era  [1] . Pioneering studies showed that lethally irradiated 
mice could survive radiation-induced bone marrow apla-
sia if the spleen was shielded by a lead foil or, later, after 
transfusion of bone marrow from mice of the same strain 
 [2–5] . After it had initially been debated whether the pro-
tective effect was due to ‘a substance of noncellular na-
ture’ (humoral hypothesis) or transplanted cells (cellular 
hypothesis), several laboratories subsequently used cyto-
genetic markers to unequivocally demonstrate that the 
radioprotective effect of bone marrow transplantation re-
sulted from the replacement of the damaged hematopoi-
etic system of the host by healthy cells from the donor  [6] . 
These early animal studies formed the rational basis for 
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 Abstract 
 Graft-versus-host disease (GVHD) is defined by the aggrega-
tion of clinical and pathological manifestations in a recipient 
of allogeneic stem cells or bone marrow transplantation in 
which specific immunological as well as nonspecific phe-
nomena lead to characteristic features. GVHD is one of the 
major complications after hematopoietic stem cell trans-
plantations and responsible for posttherapeutic morbidity, 
mortality and decrease in quality of life of those patients. 
GVHD is critically induced and maintained by donor immu-
nocompetent cells that particularly attack epithelia of fast 
proliferating tissues such as those from the liver, gastrointes-
tinal tract and skin. On the basis of the time of presentation, 
cutaneous GVHD has been originally divided into an acute 
and chronic disease. The latter has traditionally been further 
subclassified into a more epithelial or lichenoid and a pre-
dominantly dermal or sclerodermoid form. With respect to 
the growing importance of this therapeutic procedure and 
increasing numbers of outpatients presenting with chronic 
GVHD, this article summarizes the updated knowledge on 
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the first attempts to treat human leukemias with high-
dose chemoradiotherapy followed by syngeneic or alloge-
neic (for glossary, see  table 1 ) bone marrow transplanta-
tion, and clinical investigators on both sides of the Atlan-
tic Ocean soon communicated their initial promising 
results. For example, George Mathé published the suc-
cessful use of allogeneic marrow infusions to rescue vic-
tims of accidental irradiation exposure in Europe some 
years later than E. Donnell Thomas from the USA, who 
was awarded the Nobel Prize in Physiology or Medicine 
together with Joseph E. Murray in 1990 for groundbreak-
ing work on organ and cell transplantation in the treat-
ment of human disease  [7, 8] . Final proof of concept came 
with the first successful bone marrow transplantation 
from a human leukocyte antigen (HLA)-mismatched sib-
ling donor followed by several HLA-identical sibling 
transplantations in children with severe combined im-
munodeficiency in 1968  [9] .
 Over the last decades, allogeneic HSCT has become an 
important therapeutic modality not only for the treat-
ment of hematological malignancies (e.g. leukemias or 
lymphomas), but also for the treatment of nonmalignant 
hematological stem cell disorders (e.g. severe aplastic 
anemia), genetic diseases (e.g. severe combined immuno-
deficiency or thalassemia) and, under certain conditions, 
even solid tumors (e.g. renal cell cancer)  [10–13] . The 
growing importance of HSCT is emphasized by an ongo-
ing increase in its use over the last 20 years  [14] . Today, 
transplanted stem cells are used from autologous, synge-
neic and allogeneic sources and are collected from bone 
marrow, peripheral blood after mobilization or umbilical 
cord blood. Moreover, allogeneic HSCT is increasingly 
performed with success over HLA barriers due to limited 
numbers of HLA-matched siblings, e.g. from parents 
(haploidentical), HLA-mismatched siblings, and matched 
or mismatched unrelated donors. What has been a high-
ly experimental therapy only a few decades ago has now 
emerged as standard of care for many diseases  [11, 15] .
 Currently, the main limitations of allogeneic HSCT 
include treatment-related toxicity, relapse of the underly-
ing disease (in the setting of malignant stem cell disor-
ders) and immunological complications such as rejec-
tion, graft-versus-host disease (GVHD) and delayed im-
mune reconstitution. GVHD in its acute or chronic form 
is the main cause of nonrelapse morbidity and mortality 
both as a direct complication (e.g. bronchiolitis obliter-
ans) or via associated immunodeficiency and suscepti-
bility to severe infections  [16, 17] . With the increasing 
number of patients undergoing HSCT and the more 
widespread use of mismatched transplantation, the der-
matologist will be more and more confronted with GVHD 
in her/his daily practice, and it is thus the goal of the 
 current article to provide a concise overview of the 
pathomechanisms underlying GVHD, changing disease 
concepts, and main clinical and pathological features 
with focus on the skin, as well as to summarize and dis-
cuss recently published consensus documents from the 
National Institute of Health (NIH) on various aspects of 
chronic GVHD  [18–25] . While some general therapeutic 
considerations are presented in the final chapter, an ex-
haustive discussion of current treatment modalities or 
prophylaxis of acute and chronic GVHD is beyond the 
scope of this article, and the interested reader is referred 
to recent reviews concerning these topics  [26–28] .
 Basic Requirements of GVHD 
 GVHD reflects an interaction between the donor and 
recipient that was first described in animals by Rupert E. 
Billingham, who observed that mice from genetically dis-
parate but not syngeneic donors developed a secondary 
lethal disease characterized by wasting, diarrhea and 
skin lesions following recovery from radiation-induced 
aplasia  [29] . He realized the similarity of this ‘wasting 
disease’ with other poorly understood phenomena such 
as ‘runt disease’ in newborn mice injected with alloge-
neic spleen cells, the ‘F 1 hybrid disease’ or the ‘parabiosis 
intoxication’  [29] . In 1966, he proposed the requirements 
under which GVHD can occur: first, the transplanted 
graft must contain immunologically competent cells; 
second, the recipient must express tissue antigens that are 
not present in the transplant donor and thus can be rec-
ognized as foreign; third, the recipient must be incapable 
of rejecting the transplanted cells  [30] . These proposi-
tions held true over time, and it is nowadays recognized 
that the mediators of GVHD are mature T cells that clon-
ally expand in an antigen-specific manner after recogni-
tion of nonself HLAs expressed on the cell surface of nu-
cleated cells in the host that is chemically or physiologi-
cally immunocompromised  [31, 32] .
 The Increasing Significance of Chronic GVHD
for the Dermatologist 
 Contrary to some expectations, the incidence of 
GVHD did not significantly decrease over the last 20 
years and still develops in about half of all patients un-
dergoing allogeneic HSCT  [33] . While novel transplanta-
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Table 1. Glossary
Technical term Description
Hematopoietic cell transplantation Superior term for transfer of hematopoietic cells within one individual or from one individual to 
another
HSCT Process of infusing healthy hematopoietic stem cells into patients who have undergone previous 
chemo- or radiotherapy mainly for hematological disorders; stem cells are infused into the venous 
bloodstream from where they move to the bone marrow and form new blood cells
Stem cell sources Depending on donor type, 3 types of stem cell transplants can be distinguished: autologous, 
 allogeneic and syngeneic; depending on the site and mode of harvest, 3 different types of HSCT can 
be distinguished: BMT, PBSCT, CBT
BMT Stem cells are collected from bone marrow by repetitive punctions of the bone marrow in general 
anesthesia
PBSCT Stem cells are collected from the peripheral blood with a cell separator after mobilization of stem 
cells with G-CSF to the peripheral blood
CBT Stem cells are collected from umbilical cord blood and placenta of the newborn immediately after 
delivery
Donor type
Autologous transplantation The patient’s own cells are used for HSCT
Syngeneic transplantation The cells of a twin are used for HSCT
Allogeneic transplantation The cells from another person are used as stem cell source (bone marrow, peripheral blood, cord 
blood), either from the same family or from an unrelated donor
HLA-identical sibling HLA (MHC)-matched cells from sibling
HLA-identical other family member HLA (MHC)-matched cells from another family member
Non-HLA-identical family member HLA (MHC)-mismatched cells from a family member
Unrelated donor HLA (MHC)-matched or -mismatched cells from an unrelated donor
Xenogeneic HCT from one species (e.g. human) to another (nonhuman)
Matching criteria
Matched related/unrelated donor HLA compatibility between donor and recipient (only in terms of HLA antigens)
Mismatched related/unrelated donor HLA incompatibility between donor and recipient (only in terms of HLA antigens)
Genotypically identical The same two haplotypes have been inherited by the donor and the recipient from the same  parental 
chromosomes (siblings with the same parents)
Phenotypically identical Both haplotypes are identical in the donor and the recipient but they are not inherited from the 
same parental chromosomes (unrelated donors are by definition at best phenotypically identical)
6/6, 10/10, 12/12 Degree of match between 6, 10 or 12 HLA antigens
MHC antigens; identical with
HLA antigens
Molecules that are expressed by all nucleated cells (MHC class I) or by a subset of hematopoietic 
cells and thymic stroma cells (MHC class II) which are recognized by CD8+ T cells (MHC I) or 
predominantly by CD4+ T cells (MHC II)
Minor histocompatibility antigens Peptides derived from polymorphic intracellular proteins that are presented on the cell membrane 
in the context of HLA class I or II molecules and that can be recognized as alloantigens by T cells 
of an HLA-matched/identical individual; they have a role for the GVHD and GVT effect
Conditioning regimens Pretransplantation treatment with chemoradiotherapy to reduce tumor burden and lower immu-
noreactivity of the host in order to allow engraftment of the transplant
Myeloablative conditioning
(traditional) regimen
Primary targets are the elimination of the tumor cells as well as induction of a state of immunosup-
pression in the host that allows the transplantation
Reduced-intensity conditioning The primary target is to induce a state of immunosuppression in the host to allow transplantation; 
elimination of the recipient stem cells as well as of residual tumor cells is mainly performed by im-
munocompetent donor cells
GVHD Immunocompetent donor cells react against tissues of the recipient
GVT reaction/effect Immunocompetent donor cells react against malignant tumor cells of the host
BMT = Bone marrow transplantation; PBSCT = peripheral blood stem cell transplantation; CBT = cord blood transplantation; G-CSF = 
granulocyte colony-stimulating factor; HLA = human leukocyte antigen; MHC = major histocompatibility complex; HCT = hematopoietic 
cell transplantation; GVHD = graft-versus-host disease; GVT = graft-versus-tumor.
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tion techniques such as reduced-intensity conditioning 
regimens are associated with less severe acute GVHD rel-
ative to myeloablative regimens, the incidence of acute 
GVHD has remained unchanged ( table 2 )  [33, 35] . By 
comparison, extended eligibility criteria for patients un-
dergoing transplantation (e.g. increased upper age limit), 
increased HLA disparity, prolonged initial survival due 
to reduction of early mortality as a consequence of better 
prophylaxis and treatment strategies of immediate com-
plications of transplantation (e.g. acute GVHD and infec-
tions), and increased use of peripheral blood stem cells 
have increased the risk for chronic GVHD  [36] . 
 The role of the dermatologists is limited in acute 
GVHD and mainly lies in the precise assessment of cuta-
neous involvement and the exclusion of other skin pa-
thologies. In contrast, the dermatologist needs to be in-
creasingly aware of the manyfold faces and long-term 
problems associated with chronic GVHD. Sustained in-
volvement of the skin, including mucosal and adnexal 
sites, is common in chronic GVHD, and dermatologists 
have to play an active role in the long-term outpatient 
management and treatment of that disease, in particular 
because persistent cutaneous lesions are pivotal for mor-
bidity  and  quality  of  life  (QOL)   of   those   patients    [37,  
38] . Furthermore, dermatologists will appropriately be 
obliged to have a central role in the continuous monitor-
ing of treatment responses throughout the disease course 
over long periods of time based on their professional 
specification. The rising significance of chronic GVHD 
is reflected by the recent implementation of an NIH Con-
sensus Development Project on Criteria for Clinical Tri-
als in Chronic GVHD. Six working groups provided con-
sensus statements for diagnosis and staging, pathology, 
biomarkers, response criteria, ancillary therapy and sup-
portive care, and design of clinical trials in chronic 
GVHD  [20–25] . These consensus documents summarize 
the current international standard criteria for diagnosis 
and activity assessment and provide guidance in the or-
gan and overall scoring as well as treatment of chronic 
GVHD; their implications for the dermatologist will be 
discussed in later sections of this article.
Table 2. Factors predisposing recipients of allogeneic HSCT to the development of GVHD (adapted from Schaffer [34])
Main characteristics influencing the occurrence and severity of GVHD Risk for 
acute GVHD
Severity of 
acute GVHD
Risk for 
chronic GVHD
Severity of 
chronic GVHD
Characteristics of the donor and recipient
HLA disparity d d d d
Unrelated HLA-matched donor
(mismatched minor histocompatibility antigens) d d d d
Female (XX) donor to male (XY) recipient d d d d
Older age of donor or recipient d ? d ?
Prior acute GVHD – – d ?
Characteristics of the transplantation protocol
More intense preparative regimen (myeloablative
vs. reduced-intensity (‘mini’) conditioning regimens) = d ? d ?
G-CSF-mobilized peripheral blood rich in CD34+ cells
(source and dose of hematopoietic stem cells) d d d ?
Unmodified (T-cell-replete) graft d d d ?
Less aggressive administration of prophylactic
immunosuppressive agents (to prevent GVHD) d d d ?
T cell depletion (no GVT effect and high probability for 
early relapse in case of malignancy and severe infections) f f f f
Later interventions (may be intended to incite a graft-versus-malignancy effect)
Withdrawal of immunosuppressive drugs d ? d d ?
Donor T lymphocyte infusions d ? d d ?
G-CSF = Granulocyte colony-stimulating factor; GVT = graft-versus-tumor; d = increased risk/severity of GVHD; f = decreased 
risk/severity of GVHD; = = equal risk/severity of GVHD; ? = unclear effect on GVHD.
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 Basic Mechanisms of Acute and Chronic GVHD 
 The molecular mechanisms underlying acute GVHD 
are much better investigated and understood than the 
pathogenesis of the chronic disease. Of particular note,
it is still a matter of debate whether acute and chronic 
GVHD represent two different phases of the same disease 
or two independent diseases, both related to allogeneic 
HSCT but associated with different molecular and patho-
physiological mechanisms  [39] .  Figure 1 illustrates the 
current model that includes aspects of classic alloreactiv-
ity, autoimmunity and immunodeficiency, phenomena 
that occur in various intensities in acute and chronic 
GVHD. The skin has been used in basic, animal and clin-
ical research as a model organ for GVHD since the very 
beginning, which has led to a fairly good understanding 
of some aspects of that disease  [40, 41] .  Figure 2 outlines 
the main principles of acute GVHD in a simplified 3-step 
process  [42, 43] . Conditioning regimens such as total 
body irradiation result in initial toxic epithelial injuries 
of highly proliferating organs such as the gut, liver and 
skin, thereby causing a cell-damage-induced proinflam-
matory cytokine milieu. These events in turn activate ke-
ratinocytes, dermal dendritic and particularly antigen-
presenting epidermal dendritic Langerhans cells as well 
as antigen-presenting cells of the gut and liver, with ensu-
ing increased expression of several cell surface proteins. 
Pivotal among these are major-histocompatibility-com-
plex-related gene products (including HLA antigens) 
which also present minor histocompatibility antigens 
(miHA)  [43–45] . The enhanced expression of HLA anti-
gens by activated host antigen-presenting cells then acti-
vate donor T cells to increase the secretion of Th1 cyto-
kines such as IFN-  , IL-2 and TNF-  , eventually leading 
to the expansion of antigen-specific alloreactive T cells. 
These events are followed by the generation of cytotoxic 
and inflammatory cytokines, cytotoxic effector cells that 
dispose of Fas- and perforin-mediated killing mecha-
nisms, large granular lymphocytes and nitric oxide. Ul-
timately, epithelial cell apoptosis, cell death and tissue 
damage are induced by the orchestrated interaction of al-
loreactive donor T cells, inflammatory cytokines and 
cells of the innate immune system (large granular lym-
phocytes, natural killer cells)  [43, 46] . It is important to 
realize that even in the absence of an HLA mismatch be-
tween the donor and recipient, cutaneous GVHD can de-
velop in the setting of miHA mismatching, as evidenced 
by human skin explant assays using minor-antigen-spe-
cific cytotoxic T cells (CTLs)  [47] . Finally, it has been 
shown that isolated cutaneous GVHD can occur in skin 
expressing ubiquitous minor antigens (H–Y) that were 
recognized by their respective CTLs, but not in the set-
ting of hematopoietic restricted miHA-specific CTLs 
(HA-1, HA-2) that did not attack the skin. The role of 
miHA in the setting of allogeneic transplantation is best 
exemplified by the increased incidence and severity of 
GVHD in male recipients of female grafts  [48] .
 Attention has recently been drawn to the role of regu-
latory T cells (T reg ) in acute GVHD. Naturally occurring 
CD4+ CD25+ T reg cells, which are phenotypically best 
characterized by their FoxP3 expression (the forkhead/
winged helix transcription factor gene that is specifically 
required for their thymic development), have been shown 
to occur at a lower frequency in the peripheral blood of 
patients with acute GVHD compared to patients without 
GVHD, an observation that may suggest their potential 
benefit in the prevention and treatment of that disease. 
More specifically, naturally occurring thymus-derived 
CD4+ CD25+ FoxP3+ T reg cells are currently investi-
gated for their potential to induce and maintain toler-
ance to allo- (and self-)antigens and to suppress allo- 
(and auto-)reactivity  [49] .
 Similar to acute GVHD, chronic GVHD is also thought 
to be an immune-mediated process that mostly involves 
alloreactive cells, with donor-derived CD4+ and CD8+ T 
cells as main effectors  [50] . As a hallmark feature, the 
chronic disease may present with clinical and laboratory 
findings that resemble various autoimmune disorders, 
e.g. bronchiolitis obliterans, Sjögren’s syndrome, im-
mune cytopenias and cutaneous sclerosis, suggesting 
that dysfunctional humoral immunity might be involved 
in the pathogenesis as well  [51–53] . Indeed, a high preva-
lence of autoantibodies against a variety of antigens has 
been observed in these patients and is thought to be the 
result of autoreactive CD4+ T cells that arose in the set-
ting of an injured thymus with impaired negative selec-
tion  [54] . In contrast to acute GVHD, however, it has been 
suggested that chronic GVHD is primarily a Th2-type 
immune-mediated disease, as evidenced by increased 
levels of IL-4, IL-5, eosinophils and elevated expression 
of transforming growth factor   in lesional scleroder-
moid skin  [55, 56] . In addition, Biedermann et al.  [57] 
hypothesized that CTL-mediated endothelial injury and 
subsequent loss of dermal vessels with impaired blood 
perfusion could be contributory to tissue fibrosis. The 
shift from an initially Th1-mediated acute disease to a 
predominantly Th2-mediated chronic immune disease 
has recently been evidenced in a murine sclerodermoid 
model by sequential global gene expression analysis. Cy-
tokine messenger RNAs for profibrotic growth factors, 
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Acute GVHD: rash, GI, liver Chronic GVHD:  skin, eyes, mouth, GI,
liver, musculoskeletal, 
lungs, GU
Alloreactivity
Autoimmunity
Immunodeficiency
• Classic acute • Late acute
• Chronic overlap
• Classic chronic
Acitivity
(inflammation)
Damage
(fibrosis)Injury Repair
Changing concepts:
GVHD syndrome after allo-HCT
t
Day 0 50 100 180 1 year 2 years 3 years 5 years
 Fig. 1. The current concept of GVHD 
adapted from http://ccr.cancer.gov/re-
sources/gvhd/about.asp. GI = Gastrointes-
tinal; GU = genitourinary. 
TNF-, IL-1DC DC
Phase 1: effects of HSCT conditioning
MHC
Ag
MHC
Conditioning regimen
Secondary signal
Keratinocyte necrosis and apoptosis of recipient
Donor cytotoxic T cells
Phase 3: cellular and inflammatory effectors
TNF-
IL-1
Donor T cell
Ag
TCR
MHC
Host Ag-presenting cell
2nd signal
Phase 2: donor T cell activation
IFN-
IL-2
 Fig. 2. Three-step model of the pathophys-
iology of acute cutaneous GVHD. DC = 
Dendritic cell; Ag = antigen; MHC = major 
histocompatibility complex; TCR = T cell 
receptor. Phase 1: the conditioning regi-
men results in keratinocyte injury within 
a proinflammatory milieu (e.g. TNF-  , 
IL-1) that induces antigen-presenting den-
dritic cells to express costimulatory mol-
ecules (e.g. CD80/86, CD40) and increased 
cell surface levels of major histocompati-
bility class I and II molecules. Phase 2: af-
ter allogeneic HSCT, antigen presentation 
by host dendritic cells leads to activation of 
donor T cells and production of Th1 cyto-
kines (e.g. IFN-  , IL-2). Phase 3: donor cy-
totoxic T cells mediate direct keratinocyte 
necrosis/apoptosis (by using e.g. perforins 
and granzymes) together with cytokines 
(e.g. TNF-  ) and other cells of the innate 
immune system (for details, see text). 
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such as platelet-derived growth factor c, connective tissue 
growth factor or fibroblast growth factor, have been 
shown to be elevated similar to human scleroderma  [41] . 
However, platelet-derived growth factor receptor anti-
bodies stimulating type I collagen gene expression and 
myofibroblast phenotype conversion in normal human 
primary fibroblasts that have been found in patients with 
systemic sclerosis are not yet known in fibrosing variants 
of chronic cutaneous GVHD  [58] .
 Similar to the acute counterpart, there is an increasing 
scientific interest in the potential role of T reg cells in 
chronic GVHD  [59] . However, their ability to influence 
chronic GVHD remains elusive. So far, it potentially 
turns out that the dysbalance between regulatory (tolero-
genic) cells and alloreactive effector cells will enhance the 
risk of onset and persistence of chronic GVHD  [60, 61] . 
Finally, there is also evidence that B cells can contribute 
to the development of GVHD, predominantly in its 
chronic form, particularly in male patients with trans-
plants from female donors while conversely host B cells 
may also have the potential to attenuate GVHD by secret-
ing IL-10  [62, 63] .
 Clinical Manifestations of Cutaneous GVHD  
 Clinically, GVHD presents either as an acute disease 
within days to weeks after allogeneic HSCT mainly dur-
ing the inpatient phase or, alternatively, as a more hetero-
geneous chronic syndrome that usually occurs months to 
years after discharge from the hospital. Most challenging 
with respect to the potential differential diagnosis (e.g. 
viral infections, drug reactions) is a skin rash that usu-
ally occurs within the first 10–14 days after transplanta-
tion at the time of marrow engraftment but before the 
appearance of peripheral lymphocytes. Some authorities 
term this poorly characterized eruption that often occurs 
in the setting of multiple HLA mismatched antigens ‘hy-
peracute type of acute GVHD’ or ‘early mismatch GVHD’ 
which is generally characterized by an erythematous 
maculopapular eruption that occasionally becomes gen-
eralized, and is associated with high fever, hepatitis and 
intestinal symptoms. It remains open whether the so-
called engraftment syndrome in autologous HSCT par-
ticularly following the administration of cyclosporine 
represents a similar phenomenon or not  [64, 65] . Typi-
cally, however, acute GVHD develops between day 14 and 
day 42 after transplantation; the timing depends on the 
conditioning regimen, with a peak incidence around day 
30 after myeloablative transplantation and most often 
later in the setting of reduced-intensity nonmyeloablative 
regimens or delayed engraftment of umbilical cord blood-
derived stem cells. The skin can be the only target organ 
in acute GVHD or is often attacked before the liver and/
or gastrointestinal tract. The spectrum of skin lesions af-
ter traditional conditioning regimens  was recognized 
over 30 years ago and has been reviewed for the derma-
tologist previously  [66,67] ; these cutaneous features are 
still considered the most prominent characteristics of the 
disease.  Usually, a symmetrical morbilliform or maculo-
papular rash with a rather sudden onset is found that pre-
dominantly involves the upper back and lateral neck but 
is sometimes accentuated on the palms, soles, pinnae and 
cheeks ( fig. 3 ). The eruption may begin acrally but even-
tually shows a generalized distribution. Prominent acral 
erythema, a violaceous discoloration of the pinnae and 
folliculocentric blanching erythema with tiny macules 
and small papules can be suggestive of that disease. In 
severer cases, the exanthema can progress to a diffuse 
erythroderma with bulla formation, a positive Nikolsky 
sign and desquamation that resembles drug-induced tox-
ic epidermal necrolysis. The mucous membranes and 
particularly the conjunctivae can be involved as well, and 
the former can be difficult to differentiate from condi-
tioning-related mucositis  [68, 69] . The skin involvement 
in acute GVHD is measured according to the extent of 
the lesions (stage 1 = 25% of body surface area; stage 2 = 
25–50%; stage 3 = 50% up to erythroderma; stage 4 = 
erythroderma with bullae) and is included, besides liver 
and gastrointestinal symptoms/disease, in the prognosti-
cally relevant overall grading of acute GVHD ( table 3 ). 
Approximately half of the patients with moderate to se-
vere GVHD (grades 2–4) may die as a consequence of this 
treatment-related toxicity  [46, 68] . 
 Early lesions of chronic GVHD are often subtle and 
may include dryness of skin (xerosis), follicular promi-
nence (keratosis-pilaris-like lesions), ichthyosis and pap-
ulosquamous lesions  [68] . Psoriasiform and pityriasis-ro-
sea-like skin changes as well as annular lesions resem-
bling annular psoriasis, the superficial type of erythema 
annulare centrifugum or subacute cutaneous lupus ery-
thematosus may be present before the more classical pre-
sentations develop, namely lichen-planus-like and sclero-
dermoid changes ( fig. 4 )  [19] . Lichenoid lesions are char-
acterized by erythematous or violaceous lichenoid papules 
and plaques that usually affect the dorsal aspects of the 
hands, forearms and trunk. They may show folliculotro-
pism, rarely follow Blaschko’s lines or appear in the der-
matomal site of a previous herpes zoster infection  [72] . 
Sclerodermoid chronic GVHD often presents with plaques 
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of dermal sclerosis that resembles morphea and eventu-
ally progresses to generalized scleroderma or, alternative-
ly, presents with lichen-sclerosus-like features in a genital 
or extragenital distribution. Since its initial recognition, 
the spectrum of the fibrosing GVHD variants has been 
continuously extended, and both lichen-sclerosus-type as 
well as eosinophilic-fasciitis-type sclerotic lesions are now 
considered diagnostic features and often result in joint 
contractures  [73] . Poikilodermatous changes can be hall-
mark signs of chronic GVHD and are predominantly ob-
served on the face, lateral neck and trunk, exceptionally 
in addition to multiple hemangiomas. Adnexal involve-
ment with various nail changes, different types of scar-
ring and nonscarring alopecia, and impairment of sweat-
ing are also constant findings, as is involvement of the oral 
and genital epithelium in up to 80% of patients  [69] . Mu-
cous membrane involvement with dryness, atrophy, hy-
pertrophy, lichenoid changes, lacy white plaques and ero-
sions as well as ulcerative lesions, dental caries and peri-
odontitis/gingivitis can all have a significant impact on 
nutrition behavior, sexuality and overall QOL  [74, 75] . 
The complete clinical spectrum of skin, adnexal and mu-
cosal involvement in chronic GVHD has recently been 
reviewed by the NIH Consensus Conference and is out-
lined in  table 4  [20] . One of the most challenging aspects 
in the diagnosis and management of chronic GVHD is the 
measurement of disease activity and delineation from 
nonactive sequelae of a past chronic GVHD. Biedermann 
et al.  [76] proposed a combined assessment of activation 
markers of circulating T cells and endothelial injury mea-
sured in skin biopsies as a sensitive and specific test to 
identify patients with active chronic disease.
 Impact of Histopathology in the Diagnosis and 
Prediction of Cutaneous GVHD 
 The histological criteria for the diagnosis of acute cu-
taneous GVHD have been established in 1974 and are still 
in use today  [77] . Basically, acute GVHD reveals the pro-
totypical morphological features of interface dermatitis 
of the vacuolar type ( fig. 3 ). Damage to the skin epithe-
lium has early been shown to originate in a nonrandom 
fashion in the tips of the rete ridges exactly at the niche 
where cytokeratin 15 epidermal cells, presumably epider-
Table 3. Consensus grading and organ extent of involvement of acute GHVD (adapted from Antin and Deeg [70] and Przepiorka et 
al. [71])
Skin Liver Intestinal tract
Stage
1 rash on <25% of skin bilirubin 2–3 mg/dl diarrhea >500 ml/day or persistent nausea
2 rash on 25–50% of skin bilirubin 3–6 mg/dl diarrhea >1,000 ml/day
3 rash on >50% of skin bilirubin 6–15 mg/dl diarrhea >1,500 ml/day
4 erythroderma with bulla formation bilirubin >15 mg/dl severe abdominal pain with or without ileus
Grade
0 none none none
I stage 1–2 none none
II stage 3 or stage 1 or stage 1
III – stage 2–3 or stage 2–4
IV stage 4 or stage 4 –
Rash: use the ‘rule of nines’ to determine body surface area involvement. Bilirubin: range given as total bilirubin; downgrade one 
stage if an additional cause of elevated bilirubin has been documented. Diarrhea: volume of diarrhea applies to adults; for pediatric 
patients, the volume of diarrhea should be based on body surface area. Nausea: persistent nausea with histological evidence of GVHD 
in the stomach or duodenum. Grade IV may also include lesser organ involvement but with extreme decrease in performance status.
 Fig. 3. Hallmark clinical and pathological features of acute muco-
cutaneous GVHD: acute GVHD with characteristic edematous 
erythema of the head (panel 1), widespread partly confluent mac-
ulopapular rash on the trunk (panels 2–4), severe involvement of 
the eyes with hemorrhagic crusts (panel 5) and bullous lesions 
(panel 6) resembling toxic epidermal necrolysis; classical acral le-
sions with relatively sharp borders (panels 7–10) and prototypical 
histological changes showing vacuolar interface dermatitis with 
prominent apoptosis of keratinocytes and so-called satellite ne-
crosis of the basal and suprabasal layer (panels 11, 12). 
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mal stem cells, are thought to reside  [78] . However, while 
gene expression analysis in mouse models indicates that 
these cytokeratin-15-positive epidermal cells are early 
targets in GVHD, it is unclear whether this is the case in 
humans  [40, 79, 80] .
 Histologically, there is a stereotypical evolution of 
morphological findings of subtle endothelitis and peri-
vascular mast cell degranulation in the uppermost der-
mis that are suggestive of but not specific for the disease. 
These changes are usually followed by the vacuolization 
of the basal epithelial layer (grade 1), keratinocyte apop-
tosis and satellitosis (grade 2), up to subepidermal cleft-
ing (grade 3) and epidermal separation (grade 4). Involve-
ment of the upper portion of eccrine or follicular struc-
tures is a distinctive finding that often occurs early in the 
course of the disease and can prove helpful for diagnosis. 
Immunohistochemistry can identify the predominance 
of CD8+ lymphocytes as main effectors but its value in 
the diagnosis of acute GVHD is rather limited  [81] . On a 
microscopic level, there is considerable overlap of histo-
logical findings of early GVHD and various other post-
transplantation diseases (e.g. viral exanthems, eruptions 
due to immune reconstitution, drug reactions), overall 
decreasing the sensitivity and specificity of a skin biopsy 
in a given patient. Therefore, as there are no pathogno-
monic histological features for GVHD, the value of a bi-
opsy lies mainly in lending support to the clinical diag-
nosis of GVHD or exclusion of other diseases, depending 
on the clinical context. Importantly, the number of lym-
phocytes entering the epidermis and quantity of apo-
ptotic keratinocytes did not prove useful as predictor of 
the severity of the clinical disease, in contrast to the pre-
dictive value of substantial increases in total bilirubin, 
diarrhea and extent of rash and overall clinical GVHD 
grade for potentially fatal outcome  [82, 83] . Furthermore, 
skin biopsies of a rather unspecific rash that occurs in the 
early phase after transplantation have been shown to be 
of limited value in predicting the progression from rash 
(viral-induced, drug-induced or early acute GVHD) to 
overt acute GVHD grade 2–4 irrespective of the stem cell 
source (peripheral blood, bone marrow). Likewise, the 
histopathological assessment of normal skin before allo-
geneic HSCT could not predict the development of GVHD 
 [81, 84] . So far, in patients with clinicopathological acute 
GVHD, there are no known morphological or immuno-
histochemical features predicting the risk of subsequent 
chronic GVHD. Only in the setting of nonmyeloablative 
conditioning a small retrospective study found that his-
tologically ‘proven’ clinical acute GVHD with morpho-
logical features of both acute and chronic disease (‘com-
 Fig. 4. Selected spectrum of clinical and pathological lesions in 
chronic cutaneous GVHD: chronic GVHD with characteristic 
morphea-like lesions (panel 1), sclerotic features resembling 
sclerodermia en coup de sabre (panel 2) and eosinophilic-fasci-
itis-like fibrosing lesions (panel 3) showing the ‘groove sign’; head 
erythema with scaling in a patient with late acute/chronic overlap 
disease (panel 4); lichen-planus-like changes (panel 5) and pity-
riasis-rosea-like manifestations in 2 patients more than 6 months 
after HSCT (panel 6); distinctive dyspigmentation of the head 
with features of poikiloderma resembling xeroderma pigmento-
sum (panel 7); classical mucosal lesions with lichen-type features, 
hyperkeratotic plaques and atrophy on the buccal mucosa, tongue 
and genital area (panels 8–11); longitudinal ridging, splitting and 
pterygium formation of nails (panels 12, 13) and examples of 
patchy scarring (panel 14) and nonscarring (panel 15) alopecia in 
2 patients after recovery from chemoradiotherapy; hallmark his-
tological changes with superficial sclerosis and vessel rarification 
(panels 16), classical lichenoid-type changes (panel 17) and chang-
es of late acute/chronic overlap disease with interface dermatitis 
partly of the vacuolar and lichenoid type (panel 18). 
Table 4. Diagnostic criteria for chronic GVHD of the skin, nails, 
scalp/hairs and mouth (adapted from Filipovich et al. [20])
A diagnosis of chronic GVHD requires
– At least 1 ‘diagnostic’ manifestation or
– At least 1 ‘distinctive’ manifestation plus confirmation of the 
GVHD diagnosis by biopsy/laboratory tests/imaging in the 
same or another organ
‘Diagnostic’ mucocutaneous manifestations
– Lichen-planus-like lesions
– Lichen-sclerosus-like lesions
– Morphea-like lesions
– Sclerotic lesions including deep lesions (eosinophilic fasciitis)
– Poikiloderma
– Oral hyperkeratotic plaques
– Oral lichen-type features
– Restriction of mouth opening due to sclerosis
‘Distinctive’ mucocutaneous manifestations
– Depigmentation
– New-onset scarring and nonscarring scalp alopecia or papulo-
squamous lesions or scaling of the scalp
– Nail dystrophy, longitudinal ridging, splitting or brittle fea-
tures, onycholysis, pterygium unguis and nail loss
– Xerostomia, mucoceles, oral mucosal atrophy, oral ulcers and 
pseudomembranes
In the absence of clinical or histological signs/symptoms of 
chronic GVHD, the persistence, recurrence or new onset of char-
acteristic manifestations of acute GVHD should be classified as 
acute GVHD, regardless of the time after the transplantation.
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posite’ histological features) may predict the subsequent 
development of chronic GVHD  [85] . In daily routine, the 
best way to provide an accurate diagnosis of acute GVHD 
may encompass a combined approach that includes mu-
cocutaneous assessment, histopathological evaluation 
and exclusion of other diseases in the hands of experi-
enced physicians and that sometimes requires repeat 
evaluations for an adequate diagnosis.
 The histopathology of chronic GVHD has tradition-
ally been divided into an epidermal (lichen-planus-like) 
and a dermal (sclerodermoid) type ( fig. 4 ). Subtle histo-
logical features that are mainly regarded as hallmark 
changes in acute GVHD, e.g. satellitosis and vacuoliza-
tion of the basal layer, may also be found in both chronic 
types, but are far more predominant in the epidermal 
type, as is adnexal involvement, e.g. cytotoxic acrosyrin-
gitis or folliculitis. However, spongiotic alterations may 
be found, and marked thickening of the stratum corne-
um, stratum granulosum and stratum spinosum togeth-
er with a band-like infiltrate and perifollicular fibrosis 
are indicative features of lichen-planus-like chronic 
GVHD, whereas thickening, homogenization and com-
paction of the collagen bundles are hallmark findings in 
the sclerodermoid type.
 The NIH Pathology working group has recommended 
to confirm clinically suspected chronic GVHD by histol-
ogy; however, the role of subsequent biopsies to assess the 
response to treatment has not yet been determined  [21] . 
The group emphasized that histological interpretation 
requires the consideration of the clinical context to min-
imize false-negative and false-positive diagnoses (e.g. 
drug reactions, concurrent infections or inflammatory 
reactions unrelated to GVHD). The proposed histologi-
cal criteria for skin and oral mucosa now differentiate 
between minimal criteria for active disease and specific 
criteria for chronic GVHD ( table 5 ) and, together with 
clinical, laboratory and radiographic information, are an 
integral part to yield 4 diagnostic categories, i.e. ‘no 
GVHD’, ‘possible GVHD’, ‘consistent with GVHD’ and 
‘definite GVHD’. Importantly, the diagnosis and staging 
committee recommended that keratinocyte apoptosis 
without other features of chronic GVHD found on day 
80–100 screening skin biopsies does not indicate chronic 
GVHD and in that particular situation should not be tak-
en to predict that alloreactive T-cell-induced flares may 
follow cessation of immunosuppressive therapy  [20] .
 New Classification Systems for GVHD 
 Whereas the term acute GVHD has historically been 
used to describe a syndrome of dermatitis, cholestatic 
hepatitis and gastroenteritis that developed within the 
first 100 days after allogeneic HSCT, chronic GVHD has 
traditionally been used to describe a syndrome that oc-
curred after day 100 and often contained features of auto-
Table 5. Histological criteria for GVHD of skin and oral mucosa (adapted from Shulman et al. [21])
Organ/lesion Minimal criteria for active GVHD Specific criteria for chronic GVHD
Skin, any stage Apoptosis in epidermal basal or lower malphigian
layer or outer root sheath of hair follicle or
acrosyringium 8 lichenoid inflammation 8
vacuolar change 8 lymphocytic satellitosis
Lichen-planus-
like
Combination of epidermal orthokeratosis, hypergranulosis 
and acanthosis with lichenoid changes 8 syringitis of  eccrine 
units 8 panniculitis
Sclerotic Collagenous deposition with thickening throughout the
papillary dermis or pan-dermal collagenosis 8 panniculitis
Morpheic Sclerosis in the lower reticular dermis or along the dermal-
hypodermal border 8 epidermal and adnexal involvement
Fasciitis Fibrous thickening of fascial septa with adjacent inflamma-
tion 8 panniculitis
Oral mucosa Lymphocytic infiltration of mucosa with variable
apoptosis
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immunity. This somewhat arbitrary time delineation was 
of high clinical value in the early era of myeloablative con-
ditioning regimens in the setting of bone marrow or pe-
ripheral blood HSCT. Nowadays, in the era of increased 
numbers of haploidentical, cord blood, nonmyeloablative 
and unrelated transplants, so-called stem cell boosts and 
donor lymphocyte infusions, disease manifestations that 
were commonly observed in acute GVHD, can often de-
velop after day 100 following transplantation, whereas, 
conversely, signs and symptoms of chronic GVHD may be 
present shortly after donor lymphocyte infusion. This 
paradigm shift is respected in the new categories of acute 
and chronic GVHD that were proposed by the recent NIH 
consensus conference and are outlined in  figure 1 and  ta-
ble 6  [20] . Moreover, the distinction between limited and 
extensive chronic GVHD  [86] that was introduced in 1980 
on the basis of a retrospective observational study of only 
20 patients is now proposed to be displaced by an organ 
scoring system ( table 7 ). This proposed global scoring sys-
tem reflects the clinical effects of chronic GVHD on the 
patient’s functional status and finally classifies patients as 
having mild, moderate or severe chronic GVHD  [20, 86] . 
In the absence of clinical or histological features sugges-
tive of chronic GVHD, the new onset, persistence and re-
currence of characteristic manifestations of acute GVHD 
should now be considered as acute GVHD regardless of 
the time after transplantation  [20] . The lack of standard-
ized criteria for quantitative measurement of therapeutic 
response in clinical trials remained a major problem and 
obstacle for the efficient development and introduction of 
new agents in this disease  [23] . The proposed organ scor-
ing and response criteria address this issue at least in part, 
but it remains to be demonstrated in the future whether 
the course of the disease and the influence of drugs can 
be more precisely recorded.
 Basic Preventive and Therapeutic Approaches to 
(Cutaneous) GVHD 
 Two fundamentally different approaches for the pre-
vention of GVHD have been established: immunosup-
pression with cyclophilin inhibitors such as cyclosporine 
or FK506 with or without methotrexate or T cell deple-
tion. Both approaches have their specific advantages and 
disadvantages. Cyclophilin inhibitors interfere with the 
activation and expansion of donor T cells and are very 
effective in the prevention of GVHD but need to be taken 
over a long period of time and are associated with sig-
nificant side effects, such as nephrotoxicity. In contrast 
to standard transplantation, ex vivo graft manipulation 
such as T cell depletion has lower organ toxicity but is as-
sociated with higher incidences of graft failure or graft 
rejection, delayed immune reconstitution particularly of 
the CD4+ lymphocytes, decreased functional recovery of 
T cells and, importantly, impaired recovery of T cell rep-
ertoire diversity. While increased incidences of bacterial 
or fungal infections have not been documented, there is 
an enhanced risk of posttransplantation lymphoprolif-
erative disease and leukemia relapse after transplantation 
of manipulated compared to unmanipulated stem cells, 
and the probability of reactivated viral infections such as 
cytomegalovirus appears to be increased  [87, 88] . Newer 
preventive strategies including cytokine-based approach-
es, e.g. antithymocyte globulin, anti-TNF-  antibody 
(infliximab), anti-TNF-  receptor (etanercept) or anti-
IL-2 receptor antibody (dacalizumab) to neutralize the 
conditioning-induced cytokines of the afferent phase of 
acute GVHD before infusion of the graft, are not yet 
firmly established in clinical use and may have a predom-
inant role in the treatment of steroid-refractory disease 
 [88] . Other immunosuppressive drugs such as mycophe-
Table 6. Categories of acute and chronic GVHD (adapted from Filipovich et al. [20])
Category Timing of symptoms 
after HSCT or DLI
Presence of acute
GVHD features
Presence of chronic 
GVHD features
Acute GVHD
Classic ≤100 days yes no
Persistent, recurrent or late onset >100 days yes no
Chronic GVHD
Classic no time limit no yes
Overlap syndrome no time limit yes yes
DLI = Donor lymphocyte infusion.
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nolate mofetil as prophylactic treatments alone or in 
combination with established drugs are under active in-
vestigation but have not yet been proven to be effective 
 [28] .
 The first-line treatment of significant acute ( 6 grade 
II) or chronic GVHD consists of high doses of systemic 
corticosteroids  [46, 54] . The standard therapy of acute 
cutaneous GVHD below 50% of body surface involve-
ment ( ! grade II) includes topical application of potent 
corticosteroids or tacrolimus  [89] ; by comparison, their 
application in chronic GVHD in addition to systemic 
therapy, especially at mucosal sites, is not established. 
Unfortunately, there is still no effective treatment for cor-
ticosteroid-refractory acute GVHD. A variety of agents 
has been investigated and will be tested in future, includ-
ing chemical immunosuppressants such as mycopheno-
late mofetil, sirolimus or thalidomide, broad antilym-
phocyte antibodies (antithymocyte globulin, anti-CD3 
such as OKT3 and visilizumab) and more specific agents 
directed against activation or adhesion molecules (anti-
Table 7. Organ scoring and global assessment and severity of chronic GVHD as proposed by the 2005 NIH Consensus Development 
Project (adapted from Schaffer [34])
Score 1 Score 2 Score 3
Skin <18% of BSA and no sclerotic
features
19–50% of BSA or superficial sclerosis
(able to pinch)
>50% of BSA or deep sclerosis
(unable to pinch) or impaired mo-
bility, ulceration or severe pruritus
Mouth Mild signs/symptoms not limiting
oral intake
Moderate signs/symptoms with partial
limitation of oral intake
Severe signs/symptoms with major 
limitation of oral intake
Eyes Mild dry-eye symptoms (using eye-
drops ≤3!/day) or asymptomatic
but signs of keratokonjunctivitis sicca
Moderate dry-eye symptoms partially
affecting ADL (using eyedrops ≥3!/day
or punctuate plugs), no visual impairment
Severe dry-eye symptoms signifi-
cantly affecting ADL or unable to 
work or loss of vision
GI tract Symptoms without significant weight 
loss
Symptoms with weight loss of 5–15% Symptoms with weight loss >15%, 
requiring nutritional supplemen-
tation or need for esophageal 
 dilatation
Liver Bilirubin, AP, AST or ALAT
<2! of normal upper limit
All 2–5! of normal upper limit or
bilirubin >3 mg/dl
All ≥5! of upper normal limit
Lungs1 Mild symptoms (SOB after 1 flight
of steps); FEV1 60–79% or LFS 2
Moderate symptoms (SOB after walking
on flat ground); FEV1 40–59% or LFS 6–9
Severe symptoms (SOB at rest
or requiring supplement O2);
FEV1 ≤39 or LFS 10–12
Joint/fascia Mild tightness of arms or legs,
mildly decreased ROM and not
affecting ADL
At least 1 of the following: tightness of
arms or legs, joint contractures, erythema 
due to fasciitis, moderately decreased ROM 
and mild-moderate limitation of ADL
Contractures with significantly
decreased ROM and significant 
limitation of ADL
Genital tract Mild signs/symptoms and no effect
on coitus/minimal discomfort on
examination
Moderate signs/symptoms and mild
dyspareunia/discomfort with examination
Advanced signs (strictures, labial 
fusion or severe ulceration) and 
severe pain with coitus/inability
to insert vaginal speculum
Global assess-
ment of chronic 
GVHD
Mild Moderate Severe
1–2 organs (except the lung) with
a maximum organ score each of 1
≥1 site with an organ score of 2 or ≥3 sites 
with an organ score of 1 or lung score of 1
Any organ score of 3 or lung score 
of 2
ADL = Activities of daily living; ALAT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase;
BSA = body surface area; FEV1 = forced expiratory volume in 1 s; GI = gastrointestinal; LFS = lung function score (includes FEV1 and diffu-
sion capacity of the lung for CO); ROM = range of motion; SOB = shortness of breath. 
1 When a discrepancy exists between symptoms and pulmonary function test scores (FEV1/diffusion capacity of the lung for CO), the 
higher score should be used.
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CD25, anti-IL-2 receptor, anti-CD147, anti-CD52) or cy-
tokines such as anti-TNF-  antibody (infliximab)  [26, 
50, 54, 62, 88, 90, 91] . Extracorporeal photopheresis has 
been successfully applied in chronic GVHD, particularly 
in cutaneous GVHD, and will need to be tested as first-
line treatment of specific subgroups in steroid-refractory 
GVHD  [92] . Furthermore, other light sources such as 
psoralen preparations and direct exposure to UVA have 
been proven to be effective in some patients with isolated 
cutaneous GVHD  [93] . Standard treatment of chronic 
GVHD includes cyclosporine and prednisone. Treatment 
regimens combining prednisone with cyclosporine or ta-
crolimus with mycophenolate mofetil are under current 
investigation. Other approaches including anti-TNF-  
and anti-CD20 antibodies, pentostatin and sirolimus are 
currently studied as well  [39] . Supportive care, accurate 
anti-infective treatment, balanced nutrition and topical 
emollients for the skin, mucous membranes and eyes are 
established in patients with both acute and chronic 
GVHD  [89] . Furthermore, there are early reports indicat-
ing some efficacy of mesenchymal stem cells in steroid-
refractory severe acute GVHD. Whether these beneficial 
effects will persist over time in these patients and wheth-
er they have a role in the treatment of chronic GVHD 
needs to be shown  [94, 95] .
 Outlook 
 Allogeneic HSCT will remain a therapeutic corner-
stone for an increasing number of diseases, with current-
ly over 12,000 transplantations performed worldwide per 
year, and estimates of ongoing annual growth rates of 
10–20%  [96] . Global research goals to enhance treatment 
outcome and QOL of those patients incorporates exten-
sive laboratory and clinical investigations, in particular 
to decrease the toxicity of conditioning regimens, ad-
vance donor-recipient typing and graft tolerance, reduce 
graft rejection, decrease GVHD and increase the graft-
versus-tumor (GVT) effect in the setting of malignancy. 
In particular, research activity in the field of biomarkers, 
pathobiology, response criteria and therapy are key areas 
that will be of critical importance to encounter the in-
creasing significance of chronic GVHD  [22, 97] . Based
on its multiorgan involvement with its features of both 
allo- and autoimmunity (or ‘altered immunity’), chronic 
GVHD will require a multidisciplinary approach that 
importantly includes the dermatologists. Similarly, a site-
specific long-term management of active disease and se-
quelae will require the collaboration of various special-
ists, not only physicians, but also non-physician medical 
workers such as physiotherapists, psychologists and so-
cial workers. Effective coordination of information be-
tween patient, physicians and therapists will be facilitat-
ed by a simple and precise organizational and adminis-
trative algorithm. Despite these challenges, improvement 
of QOL and survival, which are both influenced by the 
occurrence and severity of chronic GVHD, remain the 
primary aims for patients after HSCT  [38, 98] . Unfortu-
nately, we are not yet capable of separating T-cell-medi-
ated harmful GVHD and beneficial GVT effects: as a re-
sult, graft manipulation such as T cell depletion not only 
abolishes the undesirable GVHD, but also minimizes 
beneficial GVT effects in the setting of malignancy. Miss-
ing alloreactive immunocompetent T cells thus increase 
the risk for disease relapse as well as severe infections at 
least during the first few years after transplantation. 
Therefore some degree of clinical chronic GVHD is cur-
rently embraced to decrease the chance for disease re-
lapse accepting some decrease in QOL, rather than to-
tally eliminating GVHD  [38, 98, 99] . The ultimate goal is 
to find the optimal risk-benefit compromise and to ac-
cept mild chronic GVHD while maintaining the best 
possible QOL. Current and future investigations to en-
hance the GVT effect while decreasing GVHD will be 
ultimate to decrease tumor relapse and GVHD while en-
hancing survival and provide allogeneic HSCT to a 
broader patient collective. 
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